Post by miamianne67 on Mar 4, 2016 21:23:26 GMT
(Photopqr/Le Progres/Newscom)
(Photopqr/Le Progres/Newscom)
MATTHEW GALGANI12:13 PM EST
Share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)
Reprints
California-based Intuitive Surgical (ISRG) got a boost last week when a new study showed that patients undergoing procedures with its da Vinci Surgical Systems experienced fewer complications than subjects undergoing conventional operations.
That was welcome news for the leader in robotic-assisted surgery, helping settle the long-running debate about the merits of the minimally-invasive — but quite expensive — da Vinci equipment compared to traditional surgery.
But success, plus plenty of room for growth, attracts competition, and Intuitive Surgical is facing an expanding lineup of rivals, including Alphabet (GOOGL), Medtronic (MDT), TransEntrix (TRXC), Titan Medical and Mazor Robotics (MZOR).
In 2014, robotic-assisted surgeries made up only about 10% of total operations in the U.S. and European Union. WinterGreen Research has projected the market to grow from $3.2 billion in 2014 to $20 billion by 2021.
To get a piece of that growing pie, Google Life Sciences — now Alphabet’s Verily division — teamed up last year with Johnson & Johnson (JNJ) to launch Verb Surgical, which will focus on advanced surgical robotics.
Medtronic also jumped into the business last year with its purchase of surgical giant Covidien.
Smaller rivals TransEntrix, Titan and Mazor are aiming to take market share from Intuitive Surgical by offering robotic systems at a much lower cost, which could put pressure on Intuitive’s 40.4% annual pre-tax profit margin.
(Photopqr/Le Progres/Newscom)
MATTHEW GALGANI12:13 PM EST
Share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)
Reprints
California-based Intuitive Surgical (ISRG) got a boost last week when a new study showed that patients undergoing procedures with its da Vinci Surgical Systems experienced fewer complications than subjects undergoing conventional operations.
That was welcome news for the leader in robotic-assisted surgery, helping settle the long-running debate about the merits of the minimally-invasive — but quite expensive — da Vinci equipment compared to traditional surgery.
But success, plus plenty of room for growth, attracts competition, and Intuitive Surgical is facing an expanding lineup of rivals, including Alphabet (GOOGL), Medtronic (MDT), TransEntrix (TRXC), Titan Medical and Mazor Robotics (MZOR).
In 2014, robotic-assisted surgeries made up only about 10% of total operations in the U.S. and European Union. WinterGreen Research has projected the market to grow from $3.2 billion in 2014 to $20 billion by 2021.
To get a piece of that growing pie, Google Life Sciences — now Alphabet’s Verily division — teamed up last year with Johnson & Johnson (JNJ) to launch Verb Surgical, which will focus on advanced surgical robotics.
Medtronic also jumped into the business last year with its purchase of surgical giant Covidien.
Smaller rivals TransEntrix, Titan and Mazor are aiming to take market share from Intuitive Surgical by offering robotic systems at a much lower cost, which could put pressure on Intuitive’s 40.4% annual pre-tax profit margin.